Announcement • May 01
Pomdoctor Limited announced delayed 20-F filing On 04/30/2026, Pomdoctor Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC. Announcement • Mar 13
Pomdoctor Limited Announces Strategic Upgrade Focusing On Ai And Medical-Grade Smart Wearables For Chronic Disease Management Pomdoctor Limited announced a strategic upgrade centered on the core track of artificial intelligence ("AI") + medical-grade smart wearables + full-cycle chronic disease management. The Company plans to accelerate related technology research and development ("R&D") and scenario-based implementation by leveraging its extensive medical resources and strong compliance capabilities. Over the long run, Pomdoctor aims to build a closed-loop chronic disease management ecosystem integrating hardware, data, algorithms and services, expanding the Company's long-term growth horizon while delivering sustained medical value to patients. According to Global Market Insights, the global chronic disease management market was valued at USD 6.2 billion in 2024 and is projected to grow from USD 6.9 billion in 2025 to USD 18.8 billion by 2034, representing a compound annual growth rate (CAGR) of 11.7%. In China, driven by an aging population and approximately 180 million people living with chronic conditions, the country has emerged as one of the world's largest and most promising markets for chronic disease management technologies and services. Against this backdrop, traditional outpatient-based chronic disease management continues to face structural challenges, including fragmented monitoring, delayed medical intervention, and low patient adherence. The broader adoption of smart wearable technologies and emerging AI applications is now beginning to reshape the landscape, pointing toward a new paradigm for digital healthcare. According to Pomdoctor, this strategic upgrade represents a natural extension of the Company's longstanding expertise and operational experience in chronic disease management, rather than a cross-industry expansion without prior validation. All R&D and commercialization activities will strictly comply with applicable medical regulatory requirements in both China and the United States, with evidence-based medicine serving as the foundational principle. The strategic upgrade will focus on three core areas of compliant implementation: Developing a portfolio of medical-grade smart wearable devices capable of delivering accurate and continuous physiological data to support chronic disease management, particularly for high-prevalence conditions such as diabetes and cardiovascular diseases; Building an AI-powered intelligent chronic disease management system. Leveraging health data collected from wearable devices and grounded in established clinical treatment guidelines, the system is designed to function as an intelligent assistant for risk monitoring, treatment plan support, and doctor-patient collaboration, ultimately improving management efficiency and patient adherence to outpatient care; Establishing a closed-loop chronic disease management service system that integrates hardware terminals and AI systems with the Company's existing internet hospital platform, pharmaceutical supply chain, and chronic disease service infrastructure, enabling full-cycle services from monitoring and early warning to intervention and follow-up. The Company plans to support this strategic transformation through three core competitive advantages: A strong medical compliance foundation: established internet hospital qualifications, a nationwide network of licensed physicians, and a comprehensive compliance management system supported by deep understanding of clinical needs and regulatory frameworks; Collaborative R&D capabilities: a multidisciplinary team of algorithm experts, hardware engineers, and clinical medicine specialists to ensure close alignment between technological innovation and real-world clinical requirements; Advantages as a U.S.-listed company: a standardized corporate governance structure, global resource integration capabilities, and stable capital access to support technology R&D, clinical validation, and international commercialization. Announcement • Feb 07
Scott+Scott Attorneys At Law LLP Files Securities Class Action Against PomDoctor Ltd., Zhenyang Shi, Li Xu, Cogency Global, Joseph Stone Capital, LLC, and Marcum Asia CPAs, LLP Scott+Scott Attorneys at Law LLP announced that it has filed a class action lawsuit against PomDoctor Ltd., Zhenyang Shi, Li Xu, Cogency Global, Joseph Stone Capital, LLC, and Marcum Asia CPAs, LLP (collectively, the "Defendants"). The action, which was filed in the U.S. District Court for the Southern District of New York and captioned Louie v. PomDoctor Ltd. et al.,Case No. 1:26-cv-01013, asserting claims under SSSS10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased PomDoctor Securities ("POM") between October 9, 2025, and December 11, 2025, inclusive (the "Class Period"), and who were damaged thereby. The lead plaintiff deadline in this action is April 6, 2026. 
